March 10 (Reuters) - A U.S. congressional committee stepped up the pressure on Valeant Pharmaceuticals International Inc on Thursday, urging the company to explain why it was withholding documents related to an investigation into drug pricing.
The House Oversight Committee had sent a letter to Chief Executive Michael Pearson last August, seeking documents about steep hikes in prices of two of the company’s heart drugs.
The drugmaker rejected the request in September, saying the information was “highly proprietary and confidential”, the committee said in a statement on Thursday.
The committee said it had sent another letter to Pearson last week, seeking descriptions of each undisclosed document, the total number of pages of each document withheld, and the rationale behind the withholding. (1.usa.gov/222CLrJ)
Valeant’s business and accounting practices came under regulatory scrutiny late last year. The company’s shares have tumbled around 75 percent since their record-high of $263.81 in August.
They were trading down slightly at $66.75 on Thursday. (Reporting by Natalie Grover in Bengaluru; Editing by Saumyadeb Chakrabarty)